Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease - Poll - MDSpire

Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

  • By

  • Asmaa Mohamed Fteah

  • Doaa Mamdouh Aly

  • Mohamed A. Elrefaiy

  • Ali Abdel Rahim

  • April 13, 2026

  • 0 min

Share

Original Source(s)

Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

  • by Asmaa Mohamed Fteah, Doaa Mamdouh Aly, Mohamed A. Elrefaiy, Ali Abdel Rahim

  • April 13, 2026

Related Content

Schisandra chinensis Fructus and its active metabolites for the treatment of metabolic dysfunction-associated steatotic liver disease

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026

Retraction Note: Intrathoracic Migration of Gastric Sleeve Affects Weight Loss as well as GERD–an Analysis of Remnant Gastric Morphology for 100 Patients at One Year After Laparoscopic Sleeve Gastrectomy